If you own closed-end funds long enough, eventually one of them will send you a notice about a rights offering, and the language in that notice is not exactly written to put you at ease. It talks about dilution, subscription prices, and expiration dates, and if you’ve never dealt with one before, the instinct is either to ignore it or to panic. Neither is the right response. Rights offerings are a routine, if infrequent, part of owning CEFs, and understanding the mechanics takes about five minutes.
What's Actually Happening
A rights offering is how a closed-end fund raises additional capital, since — unlike a mutual fund — a CEF generally can’t just issue new shares at will once its initial offering is complete. In a typical structure, existing shareholders as of a specific record date receive one “right” for each share they own, and those rights let them subscribe for additional shares, usually at a discount to the fund’s current market price. The Cohen & Steers Quality Income Realty Fund’s summer 2026 rights offering followed this exact template: shareholders of record as of June 18, 2026 received transferable rights that could be exercised during a roughly four-week subscription window, with the option to purchase additional shares beyond their basic entitlement if other shareholders didn’t fully subscribe.
The Part Everyone Focuses On: Dilution
Every rights offering prospectus contains some version of the same warning, and it’s worth taking seriously rather than skimming past. If the subscription price is set below the fund’s net asset value per share — which is common, since the discount is what makes the offering attractive enough for shareholders to participate — then the completion of the offering causes an immediate reduction in NAV per share for every existing shareholder, whether or not they personally participate. A recent SEC filing for a BlackRock municipal fund spelled this out plainly: shareholders who don’t fully exercise their rights will own a smaller proportional interest in the fund and will experience immediate NAV dilution even if they do exercise, because the expenses of the offering itself reduce NAV across the board.
That sounds purely negative, but it isn’t the whole picture. The fund’s total assets grow because new capital is coming in, and for a fund that was capacity-constrained or that wants to add leverage-supporting scale, that additional capital can support the strategy going forward. The dilution math is a real, mechanical cost to existing shareholders — it isn’t a marketing exaggeration — but it’s a one-time cost tied to a specific corporate action, not an ongoing drag.
The Part That Gets Less Attention: Oversubscription
Here’s where a rights offering can actually work in a shareholder’s favor. Most offerings allow investors to “oversubscribe” — request more shares than their basic entitlement — which get filled from any rights that other shareholders chose not to exercise. Because the subscription price sits below the market price, and often below NAV, shareholders who oversubscribe successfully are effectively buying additional shares at a discount to what they’re worth. As one advisory firm’s plain-language breakdown puts it, the key to a closed-end fund rights offering is oversubscribing — shareholders who simply let their basic rights lapse get diluted with no offsetting benefit, while those who exercise and oversubscribe can end up ahead once the dilution and the discount are both accounted for.
Three Decisions, in Order
When a rights offering notice arrives, there are really only three choices, and it’s worth working through them in order rather than defaulting to the easiest one. First: exercise your basic rights to maintain your proportional ownership and avoid uncompensated dilution — this is the baseline move for anyone who intends to keep holding the fund. Second: consider oversubscribing if you have conviction in the fund’s strategy and want to add to the position at a below-market price, understanding that oversubscription requests are typically filled pro rata if the offering is popular and you may not get everything you ask for. Third: sell your rights if they’re transferable and you don’t want to commit additional capital — this at least captures some value from the rights rather than letting them expire worthless, though transferable rights don’t always trade with much liquidity, so check before assuming this is a clean exit.
What you should not do is nothing at all, assuming the notice is boilerplate you can file away. Doing nothing means accepting the dilution with no offsetting benefit — the worst of the three outcomes for continuing shareholders. It’s also worth checking, before deciding, whether the fund’s board or advisor is covering the offering costs, as Cohen & Steers did with its RQI offering; when the sponsor absorbs those expenses rather than passing them to the fund, the dilution shareholders actually experience is meaningfully smaller than the worst-case scenario described in the risk disclosures.
Why Funds Choose This Over Simply Issuing New Shares
It’s fair to ask why a fund doesn’t just sell new shares directly rather than going through the rights-offering process. The answer is regulatory: closed-end funds are generally prohibited from issuing new common shares below net asset value except through a rights offering to existing shareholders, a rule designed specifically to protect existing holders from being diluted by an outside party buying in at a discount they didn’t have the chance to participate in themselves. A rights offering is the mechanism that lets a fund raise capital below NAV while giving every current shareholder — not just new outside buyers — first claim on those discounted shares. Understood that way, the structure is less an inconvenience imposed on shareholders and more a protective mechanism built around them, even though the dilution math still applies to anyone who lets their rights lapse.
A Quick Gut-Check Before Deciding
Before exercising, oversubscribing, or letting the offering lapse, it’s worth asking one grounding question: would you buy more of this fund today, in the open market, at its current price, if a rights offering weren’t happening at all? If the answer is yes, exercising and likely oversubscribing makes sense, since the offering is simply giving you a cheaper way to do something you already wanted to do. If the answer is no — if you’re only tempted by the discount to the subscription price rather than genuine conviction in the fund — that’s a signal worth taking seriously before committing new capital, discount or not.
Reading the Fine Print on Subscription Price
One detail that shapes the entire calculus is how the subscription price gets set. Some rights offerings fix the price in advance; others set it based on a formula tied to the market price or NAV during the subscription period itself, which means the actual discount you’re getting isn’t fully known until the offering closes. A formula-based pricing structure introduces a small amount of uncertainty into the oversubscription decision — you’re committing to buy shares at a price that will be determined partly by market conditions between now and the expiration date, not a number you can lock in today. Reading exactly how the subscription price will be calculated, not just skimming the headline discount percentage in the announcement, is worth the extra few minutes before deciding how aggressively to participate.
The other detail worth a second look is transferability. Non-transferable rights simply expire worthless if you don’t exercise them, with no way to capture any value from them at all. Transferable rights, like the ones Cohen & Steers issued for its RQI offering, can at least be sold on the open market if you decide not to participate — though the market for a fund’s rights is often thin and short-lived, so checking whether there’s an active bid before assuming you can easily monetize unused rights is a reasonable precaution rather than an afterthought.
